These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15238776)

  • 21. Predictors of mortality among HIV-infected children receiving highly active antiretroviral therapy.
    Njom Nlend AE; Loussikila AB
    Med Mal Infect; 2017 Feb; 47(1):32-37. PubMed ID: 27609595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
    Fairall LR; Bachmann MO; Louwagie GM; van Vuuren C; Chikobvu P; Steyn D; Staniland GH; Timmerman V; Msimanga M; Seebregts CJ; Boulle A; Nhiwatiwa R; Bateman ED; Zwarenstein MF; Chapman RD
    Arch Intern Med; 2008 Jan; 168(1):86-93. PubMed ID: 18195200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004-2009.
    Schwartz SR; Kumwenda N; Kumwenda J; Chen S; Mofenson LM; Taylor AW; Fowler MG; Taha TE
    Matern Child Health J; 2016 Mar; 20(3):542-9. PubMed ID: 26525557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death.
    Cole SR; Hudgens MG; Tien PC; Anastos K; Kingsley L; Chmiel JS; Jacobson LP
    Am J Epidemiol; 2012 Mar; 175(5):381-90. PubMed ID: 22302074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care.
    Hooshyar D; Napravnik S; Miller WC; Eron JJ
    AIDS; 2006 Feb; 20(4):575-83. PubMed ID: 16470122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study.
    Ahdieh-Grant L; Tarwater PM; Schneider MF; Anastos K; Cohen M; Khalsa A; Minkoff H; Young M; Greenblatt RM;
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):500-3. PubMed ID: 15764968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sex specific mortality in HIV/AIDS patients receiving antiretroviral therapy and risk factors in Xinjiang Uygur autonomous region].
    Ni M; Chen X; Ma Y; Hu X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2015 Sep; 36(9):971-5. PubMed ID: 26814865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
    Porter K; Babiker A; Bhaskaran K; Darbyshire J; Pezzotti P; Porter K; Walker AS;
    Lancet; 2003 Oct; 362(9392):1267-74. PubMed ID: 14575971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
    Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
    AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
    Qurishi N; Kreuzberg C; Lüchters G; Effenberger W; Kupfer B; Sauerbruch T; Rockstroh JK; Spengler U
    Lancet; 2003 Nov; 362(9397):1708-13. PubMed ID: 14643119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
    Moore DM; Hogg RS; Braitstein P; Wood E; Yip B; Montaner JS
    Antivir Ther; 2006; 11(1):125-9. PubMed ID: 16518968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
    Wood E; Hogg RS; Lima VD; Kerr T; Yip B; Marshall BD; Montaner JS
    JAMA; 2008 Aug; 300(5):550-4. PubMed ID: 18677027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival probability and predictors of mortality and retention in care among patients enrolled for first-line antiretroviral therapy, Andhra Pradesh, India, 2008-2011.
    Allam RR; Murhekar MV; Bhatnagar T; Uthappa CK; Chava N; Rewari BB; Venkatesh S; Mehendale S
    Trans R Soc Trop Med Hyg; 2014 Apr; 108(4):198-205. PubMed ID: 24627424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
    Mocroft A; Staszewski S; Weber R; Gatell J; Rockstroh J; Gasiorowski J; Panos G; Monforte Ad; Rakhmanova A; Phillips AN; Lundgren JD;
    Antivir Ther; 2007; 12(3):325-33. PubMed ID: 17591022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.
    Cozzi Lepri A; Phillips AN; d'Arminio Monforte A; Castelli F; Antinori A; de Luca A; Pezzotti P; Alberici F; Cargnel A; Grima P; Piscopo R; Prestileo T; Scalise G; Vigevani M; Moroni M;
    AIDS; 2001 May; 15(8):983-90. PubMed ID: 11399980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.